Fungal Pneumonia Epidemiology Forecast 2025-2034

Endemic fungal pneumonias are typically self-limited in healthy individuals. Coccidioides immitis is the most virulent, although 90% of patients recover without treatment. However, certain patients with fungal pneumonias may develop chronic lung issues, like cavitation or pleural effusions, or have complications outside the lungs. In AIDS patients, the mortality rate can reach 70%.

Fungal Pneumonia Epidemiology Forecast Report Coverage

The “Fungal Pneumonia Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of fungal pneumonia. It projects the future incidence and prevalence rates of fungal pneumonia across various populations. The study covers age, gender, and type as major determinants of the fungal pneumonia-affected population. The report highlights patterns in the prevalence of fungal pneumonia over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of fungal pneumonia in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Fungal Pneumonia: Disease Overview

Fungal pneumonia refers to a lung infection caused by fungi such as Histoplasma, Coccidioides (Valley Fever), Blastomyces, Aspergillus, Cryptococcus, and Pneumocystis jirovecii. It typically occurs from inhaling fungal spores that lead to inflammation in the lungs. It is most common in individuals with weakened immune systems, but healthy people can also develop it. Cough, fever, shortness of breath, chest pain, and fatigue are some of the common symptoms of the disease.

Fungal Pneumonia: Treatment Overview

To eliminate the infection and prevent complications, antifungal medications are primarily used for fungal pneumonia patients. Common antifungal treatments include fluconazole, itraconazole, and amphotericin B. Fluconazole is often prescribed for Candida or Cryptococcus infections, itraconazole for Histoplasma, Blastomyces, and Coccidioides, and amphotericin B for more severe cases. In addition to antifungal medications, supportive care such as oxygen therapy and mechanical ventilation may be needed for some patients.

Epidemiology

The fungal pneumonia epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for fungal pneumonia by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for fungal pneumonia and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• The annual incidence of invasive fungal infections is 6.5 million, with 3.8 million deaths globally. In the United States, 7,199 deaths from fungal diseases were reported in 2021.
• Pneumocystis pneumonia affects 505,000 individuals annually, resulting in 214,000 deaths, which accounts for 42.4% of cases, as per a 2024 review in the Lancet Infectious Diseases journal.
• Endemic fungal diseases are more common in men, affecting 75% to 95% of cases compared to women. Additionally, estrogen appears to offer some protection against cryptococcal infections, which have a male-to-female ratio of 2-3:1.
• The mortality rate for aspergillosis in neutropenic patients, such as those undergoing leukemia chemotherapy or bone marrow transplantation, ranges from 50% to 85%.

Country-wise Fungal Pneumonia Epidemiology

The fungal pneumonia epidemiology data and findings from the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of fungal pneumonia varies between countries, owing to differences in the environmental factors, healthcare infrastructure, and the prevalence of underlying health conditions such as HIV/AIDS or other immunocompromising factors, among others. According to the Centers for Disease Control and Prevention (CDC), fungal diseases lead to over 75,000 hospitalizations and almost 9 million outpatient visits annually in the United States.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of fungal pneumonia based on several factors.
• Fungal Pneumonia Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of fungal pneumonia are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of fungal pneumonia epidemiology in the 8 major markets?
• What will be the total number of patients with fungal pneumonia across the 8 major markets during the forecast period?
• What was the country-wise prevalence of fungal pneumonia in the 8 major markets in the historical period?
• Which country will have the highest number of fungal pneumonia patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of fungal pneumonia during the forecast period of 2025-2034?
• What are the currently available treatments for fungal pneumonia?
• What are the disease risks, signs, symptoms, and unmet needs of fungal pneumonia?

This product will be delivered within 3-5 business days.